Article

Micro-thin prescription inserts provide stable vision for patients with keratoconus

Paris—The 2-year follow-up of patients who received micro-thin prescription inserts (Intacs, Addition Technology) to treat keratoconus showed that the implants improved vision and maintained stable refractions, according to Joseph Colin, MD, from CHU Bordeaux, Bordeaux, France.

Eighty-two eyes were analyzed after implantation of the prescription inserts in this prospective study.

The results were very promising in that the cylinder decreased, the spherical equivalent decreased and then stabilized, and the best-corrected visual acuity (BCVA) and the uncorrected visual acuity levels (UCVA) increased in these eyes, according to Dr. Colin, who reported his results at the European Society of Cataract and Refractive Surgeons annual meeting.

"This procedure to treat keratoconus is safe and reversible and provides stable refractions," Dr. Colin said. "Between 1 and 2 years after the implantation of Intacs, the refractions remained stable."

"Two thirds of eyes had greater than a five-line increase in BCVA and UCVA; however, loss of lines of visual acuity is also a possibility," Dr. Colin concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
© 2025 MJH Life Sciences

All rights reserved.